A Phase 2 Study of XL820 in Subjects With Advanced Gastrointestinal Stromal Tumors Resistant to or Intolerant of Imatinib and/or Sunitinib.
Phase of Trial: Phase II
Latest Information Update: 13 Aug 2012
At a glance
- Drugs XL 820 (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 13 Aug 2012 Actual end date changed from 1 Mar 2009 to 1 May 2009 as reported by ClinicalTrials.gov.
- 09 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Oct 2008 Interim results presented at the 20th EORTC-NCI-AACR Symposium 2008.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History